GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » Cyclically Adjusted Book per Share

Lixte Biotechnology Holdings (FRA:8640) Cyclically Adjusted Book per Share : €0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings Cyclically Adjusted Book per Share?

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Lixte Biotechnology Holdings's adjusted book value per share for the three months ended in Dec. 2023 was €0.202. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -13.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -102.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Lixte Biotechnology Holdings was -13.60% per year. The lowest was -205.50% per year. And the median was -92.20% per year.

As of today (2024-04-27), Lixte Biotechnology Holdings's current stock price is €6.10. Lixte Biotechnology Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €0.00. Lixte Biotechnology Holdings's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lixte Biotechnology Holdings was 128.57. The lowest was 2.95. And the median was 19.05.


Lixte Biotechnology Holdings Cyclically Adjusted Book per Share Historical Data

The historical data trend for Lixte Biotechnology Holdings's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Cyclically Adjusted Book per Share Chart

Lixte Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.49 -0.61 -

Lixte Biotechnology Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -0.69 -0.86 -2.12 -

Competitive Comparison of Lixte Biotechnology Holdings's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Lixte Biotechnology Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lixte Biotechnology Holdings's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's Cyclically Adjusted PB Ratio falls into.



Lixte Biotechnology Holdings Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lixte Biotechnology Holdings's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.202/129.4194*129.4194
=0.202

Current CPI (Dec. 2023) = 129.4194.

Lixte Biotechnology Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201403 -0.100 99.695 -0.130
201406 0.947 100.560 1.219
201409 0.608 100.428 0.784
201412 0.285 99.070 0.372
201503 -0.392 99.621 -0.509
201506 -0.483 100.684 -0.621
201509 -1.055 100.392 -1.360
201512 -1.656 99.792 -2.148
201603 -2.777 100.470 -3.577
201606 -2.522 101.688 -3.210
201609 -3.083 101.861 -3.917
201612 -3.903 101.863 -4.959
201703 -3.064 102.862 -3.855
201706 -1.548 103.349 -1.938
201709 -1.827 104.136 -2.271
201712 -2.188 104.011 -2.722
201803 -2.418 105.290 -2.972
201806 -2.882 106.317 -3.508
201809 -3.113 106.507 -3.783
201812 0.493 105.998 0.602
201903 0.166 107.251 0.200
201906 -0.083 108.070 -0.099
201909 -0.605 108.329 -0.723
201912 -0.858 108.420 -1.024
202003 -1.173 108.902 -1.394
202006 -1.448 108.767 -1.723
202009 -1.793 109.815 -2.113
202012 1.002 109.897 1.180
202103 2.573 111.754 2.980
202106 2.045 114.631 2.309
202109 1.592 115.734 1.780
202112 0.830 117.630 0.913
202203 -0.018 121.301 -0.019
202206 2.268 125.017 2.348
202209 1.766 125.227 1.825
202212 0.944 125.222 0.976
202303 0.326 127.348 0.331
202306 -0.447 128.729 -0.449
202309 0.593 129.860 0.591
202312 0.202 129.419 0.202

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Lixte Biotechnology Holdings  (FRA:8640) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lixte Biotechnology Holdings was 128.57. The lowest was 2.95. And the median was 19.05.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Lixte Biotechnology Holdings Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lixte Biotechnology Holdings (FRA:8640) Business Description

Traded in Other Exchanges
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Lixte Biotechnology Holdings (FRA:8640) Headlines

No Headlines